Q-omics provides the consensus-scored ALG1L15P profile across patient tissues and cancer cell-line models. ALG1L15P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ALG1L15P is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, ALG1L15P RNA expression shows 10,951 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LUAD, and ACC as cancer lineages where ALG1L15P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALG1L15P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALG1L15P survival associations across molecular data types. ALG1L15P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALG1L15P RNA expression–survival associations across cancer types. High ALG1L15P expression shows unfavorable associations in UVM, LGG, ACC and CHOL, but favorable associations in UCEC and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for ALG1L15P RNA expression.
This table summarizes ALG1L15P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ALG1L15P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALG1L15P shows higher tumor expression in LUAD, BRCA, COAD, HNSC, LIHC and KIRC. The LUAD box plot shows higher ALG1L15P RNA expression in tumor versus normal tissue (log2 FC = +0.197, t-test p < 0.001).
This table shows molecular features associated with ALG1L15P in patient tissues and cancer cell lines. In patient samples, ALG1L15P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
